



Cancer Prevention and Control CIRB Meeting Agenda

November 25, 2025

I. Initial Review

S2424CD, A Randomized Controlled Trial of an Intervention Called "Algorithm-Enabled Patients Activated in Cancer Care Through Teams" (A-PACT) to Improve Goals of Care Communication for People with Cancer (Version Date 10/17/25)

II. Initial ReReview

NWU24-19-01, Evaluating the Feasibility of a Survivin Peptide Vaccine (SurVaxM) as an Interception Agent in Patients at High Risk for Lung Cancer (Version Date 11/06/25)

III. Amendment

MDA20-01-01, A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP) (Version Date 10/10/25)

IV. Amendment

UMI21-05-01, Obeticholic Acid for Prevention in Barrett's Esophagus (Version Date 10/16/25)

V. Amendment

UMI23-14-02, Phase 2 Study of Low Dose Tamoxifen +/- High Dose Omega-3 Fatty Acids in Overweight Postmenopausal Women at Increased Risk for Breast Cancer (Version Date 09/30/25)

VI. Continuing Review

MDA20-02-01, Time Restricted Eating And Metformin (TEAM) in Invasive Breast Cancer (IBC) or Ductal Carcinoma in Situ (DCIS). A randomized, Phase IIb, Window of Opportunity Presurgical Trial. (Version Date 02/18/25)

VII. Continuing Review

NRG-CC008, A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCK] (Version Date 04/28/25)

VIII. Continuing Review

NWU20-02-02, A Randomized and Placebo-Controlled Phase II Trial Targeting Dominant-Negative Missense Mutant P53 By Atorvastatin for Reducing the Risk of Longstanding Ulcerative Colitis-Associated Cancer (Version Date 05/09/25)

IX. Continuing Review

UMI22-09-01, Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer (Version Date 09/29/25)

X. Continuing Review

UWI20-00-01, A Phase II Trial of the Immunogenicity of a DNA Plasmid Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes from Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Participants with Triple Negative Breast Cancer (Version Date 04/17/24)

XI. Unanticipated Problem Review

UAZ22-10-01, Phase IIa, Single-arm, Open-label, Clinical Trial of calcipotriene plus 5-fluorouracil Immunotherapy for Skin Cancer Prevention in Organ Transplant Recipients (Version Date 06/16/25)
